|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: HIST1H3A |
Gene summary for HIST1H3A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | HIST1H3A | Gene ID | 8350 |
| Gene name | H3 clustered histone 1 | |
| Gene Alias | H3/A | |
| Cytomap | 6p22.2 | |
| Gene Type | protein-coding | GO ID | GO:0006323 | UniProtAcc | P68431 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8350 | HIST1H3A | LZE7T | Human | Esophagus | ESCC | 3.90e-02 | 1.37e-01 | 0.0667 |
| 8350 | HIST1H3A | LZE21D1 | Human | Esophagus | HGIN | 1.07e-09 | 5.96e-01 | 0.0632 |
| 8350 | HIST1H3A | LZE21T | Human | Esophagus | ESCC | 1.57e-07 | 3.20e-01 | 0.0655 |
| 8350 | HIST1H3A | P1T-E | Human | Esophagus | ESCC | 1.23e-18 | 1.19e+00 | 0.0875 |
| 8350 | HIST1H3A | P10T-E | Human | Esophagus | ESCC | 3.97e-04 | 1.28e-01 | 0.116 |
| 8350 | HIST1H3A | P12T-E | Human | Esophagus | ESCC | 1.97e-10 | 2.27e-01 | 0.1122 |
| 8350 | HIST1H3A | P23T-E | Human | Esophagus | ESCC | 3.36e-03 | 1.09e-01 | 0.108 |
| 8350 | HIST1H3A | P26T-E | Human | Esophagus | ESCC | 3.50e-02 | 9.03e-02 | 0.1276 |
| 8350 | HIST1H3A | P27T-E | Human | Esophagus | ESCC | 4.40e-09 | 2.66e-01 | 0.1055 |
| 8350 | HIST1H3A | P47T-E | Human | Esophagus | ESCC | 1.96e-05 | 1.07e-01 | 0.1067 |
| 8350 | HIST1H3A | P48T-E | Human | Esophagus | ESCC | 2.03e-09 | 3.35e-01 | 0.0959 |
| 8350 | HIST1H3A | P49T-E | Human | Esophagus | ESCC | 7.48e-03 | 2.15e-01 | 0.1768 |
| 8350 | HIST1H3A | P52T-E | Human | Esophagus | ESCC | 4.40e-09 | 2.30e-01 | 0.1555 |
| 8350 | HIST1H3A | P54T-E | Human | Esophagus | ESCC | 3.18e-08 | 3.63e-01 | 0.0975 |
| 8350 | HIST1H3A | P61T-E | Human | Esophagus | ESCC | 7.34e-26 | 8.55e-01 | 0.099 |
| 8350 | HIST1H3A | P65T-E | Human | Esophagus | ESCC | 2.29e-07 | 1.97e-01 | 0.0978 |
| 8350 | HIST1H3A | P83T-E | Human | Esophagus | ESCC | 3.65e-06 | 1.74e-01 | 0.1738 |
| 8350 | HIST1H3A | P107T-E | Human | Esophagus | ESCC | 2.29e-02 | 8.84e-02 | 0.171 |
| 8350 | HIST1H3A | P128T-E | Human | Esophagus | ESCC | 4.43e-07 | 2.46e-01 | 0.1241 |
| 8350 | HIST1H3A | P130T-E | Human | Esophagus | ESCC | 3.89e-12 | 2.89e-01 | 0.1676 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| HIST1H3A | SNV | Missense_Mutation | rs199966951 | c.11N>T | p.Thr4Ile | p.T4I | P68431 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.546) | TCGA-A7-A0DA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| HIST1H3A | SNV | Missense_Mutation | novel | c.292G>A | p.Glu98Lys | p.E98K | P68431 | protein_coding | deleterious_low_confidence(0.02) | possibly_damaging(0.904) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |
| HIST1H3A | SNV | Missense_Mutation | c.32C>G | p.Ser11Cys | p.S11C | P68431 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.56) | TCGA-EK-A2PM-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| HIST1H3A | SNV | Missense_Mutation | novel | c.151N>A | p.Glu51Lys | p.E51K | P68431 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.843) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| HIST1H3A | SNV | Missense_Mutation | c.394N>T | p.Arg132Cys | p.R132C | P68431 | protein_coding | deleterious_low_confidence(0.04) | benign(0.204) | TCGA-AZ-6599-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| HIST1H3A | SNV | Missense_Mutation | c.64N>A | p.Ala22Thr | p.A22T | P68431 | protein_coding | deleterious_low_confidence(0.01) | benign(0.015) | TCGA-G4-6588-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| HIST1H3A | SNV | Missense_Mutation | rs772494976 | c.247C>A | p.Leu83Met | p.L83M | P68431 | protein_coding | deleterious_low_confidence(0.03) | possibly_damaging(0.823) | TCGA-A5-A0GB-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| HIST1H3A | SNV | Missense_Mutation | novel | c.329T>C | p.Leu110Pro | p.L110P | P68431 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.699) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
| HIST1H3A | SNV | Missense_Mutation | c.331N>A | p.Cys111Ser | p.C111S | P68431 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.874) | TCGA-05-4382-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| HIST1H3A | SNV | Missense_Mutation | c.25C>T | p.Arg9Trp | p.R9W | P68431 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.645) | TCGA-55-A4DF-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |